Bifidobacterium animalis subsp. lactis BB-12
Also called: BB-12, Bb-12, Bifidobacterium lactis BB-12, B. lactis Bb12, B. animalis subsp. lactis BB-12
Bifidobacterium animalis subsp. lactis BB-12 is a probiotic bacterial strain from a collection of dairy cultures. Bifidobacterium lactis was reclassified in 2004 as a subspecies of B. animalis, so older papers name it B. lactis Bb12. Results here are for BB-12.
- Category
- Probiotic
- Forms
- Live bacteria, used in foods and as freeze-dried powders; amounts stated in colony-forming units (CFU)
- Strongest evidence
- B Some positive trials
- Reviewed
- 2026-10-30
Class 1 Well studied in people. The 2025 review does not list all 35 trials; its supplement lists 19 meta-analyzed RCTs, one of another strain (LKM512). Abstracts we reviewed confirm 14 randomized trials (2005–2021) of BB-12 as the only added probiotic versus placebo or control product. [4]
Fact-checked 2026-10-30 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
BPregnancy and infants2 topics
CMouth and teeth1 topic
CStomach and gut1 topic
CSeveral areas, whole body or blood1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Defecation frequency in adults with low stool frequency and abdominal discomfort | C | In one RCT of 1,248 adults, 4 weeks of BB-12 (1 or 10 billion CFU/day) raised average defecation frequency versus placebo; the main responder analysis (OR 1.31, P = 0.071) and global relief of abdominal discomfort were not significant. [5] |
| Infant colic in breastfed infants (larger trial) | B | In an RCT of 192 breastfed infants with colic in China, BB-12 (1 x 10^9 CFU/day for 21 days) increased the share with at least 50% less crying and fussing versus placebo. [6] |
| Infant colic in breastfed infants (smaller trial) | B | In an RCT of 80 exclusively breastfed infants with colic in Italy, BB-12 (1 x 10^9 CFU/day for 28 days) increased the rate of at least 50% less daily crying versus placebo. [7] |
| Respiratory infections in healthy infants | C | In an RCT of 109 one-month-old infants given BB-12 tablets to 8 months, fewer respiratory infections were reported (65% vs 94%); gastrointestinal symptoms, otitis media and antibiotic use did not differ. [8] |
| Salivary Streptococcus mutans counts | C | A 2026 systematic review of randomized trials reported an association between BB-12 consumption and lower S. mutans counts and called for larger, longer studies. [9] |
Main constituents: Bifidobacterium lactis was reclassified as Bifidobacterium animalis subsp. lactis (type strain DSM 10140), a subspecies of B. animalis [1]; BB-12: complete genome sequence determined and published; the strain originates from a collection of dairy cultures [2]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Low defecation frequency trial: 1 or 10 billion CFU/day for 4 weeks; effects were similar for both doses. [5]
- Infant colic trials: 1 x 10^9 CFU/day for 21 days (192 infants) or 28 days (80 infants). [6]
- Infant infection trial: BB-12 tablets given twice daily by slow-release pacifier or spoon from 1 month of age to 8 months. [8]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingNothing found
No published information found in the sources checked.
Details and sources - Interactions with medicines1 listed
Antibiotics (timing)
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notificationsNone on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsStated
Health Canada probiotics monograph (April 24, 2026), Table 1 bacteria including Bifidobacterium animalis subsp.
Details and sources
- A systematic review (published online 2025) identified 35 double-blind, placebo-controlled RCTs of BB-12; adverse-event rates did not differ from placebo (15.2% vs 14%; OR 1.10), but half of the trials did not report adverse-event data. Its supplementary trial list includes one trial of another B. lactis strain (LKM512). [3]
- In healthy term infants, formula supplemented with B. lactis Bb12 gave growth similar to unsupplemented formula (weight gain: 4 RCTs, 266 infants). [10]
- In a randomized safety trial of 60 healthy children aged 1–5 years, 10 days of BB-12 yogurt gave no significant difference in adverse events versus control yogurt. [11]
- FDA (2023, probiotics in general): administering probiotics to preterm infants may cause infection or invasive and potentially fatal disease; FDA reported one infant death and more than two dozen other adverse events. [12]
- Health Canada's probiotics monograph: do not use if you have an immune-compromised condition (for example AIDS, lymphoma or long-term corticosteroid treatment). [13]
Interactions
| With | What happens |
|---|---|
| Antibiotics (timing) | Health Canada's probiotics monograph directs taking the bacteria in its Table 1, which includes Bifidobacterium animalis subsp. lactis, at least 2–3 hours before or after antibiotics. [13] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Identity, quality and standardization
- Health Canada requires each strain to be identified by phenotype and genotype (including whole-genome strain characterization), absence of virulence to be shown, and at least 80% of the label-declared quantity to remain at the end of shelf life. [13]
- US labels must list total microorganism weight, which can include live and dead cells; CFU may be listed voluntarily. [12]
Regulatory status
- Canada: Bifidobacterium animalis subsp. lactis is listed in Health Canada's probiotics monograph (April 24, 2026) for general uses such as 'helps support intestinal/gastrointestinal health'; labels must state the strain designation. [13]
- US: No NDI notification naming Bifidobacterium animalis subsp. lactis BB-12 was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-30); other B. animalis subsp. lactis (B. lactis) strains appear. FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [14]
- US: FDA's GRAS Notice Inventory lists GRN 856 (B. animalis subsp. lactis strain BB-12) for conventional foods at levels intended to provide 5 x 10^11 CFU/serving; FDA's letter (closed December 9, 2019): 'FDA has no questions'. [15]
- US: FDA states that under DSHEA it does not have the authority to approve dietary supplements before they are marketed; a firm is responsible for ensuring its products are not adulterated. [16]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-30). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Live Bifidobacterium animalis subsp. lactis BB-12 (formerly Bifidobacterium lactis Bb12) Probiotic bacterium (genus Bifidobacterium) [P1]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- No NDI notification naming Bifidobacterium animalis subsp. lactis BB-12 was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-30); other B. animalis subsp. lactis (B. lactis) strains appear. FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P2]
- FDA's GRAS Notice Inventory lists GRN 856 (B. animalis subsp. lactis strain BB-12) for conventional foods at levels intended to provide 5 x 10^11 CFU/serving; FDA's letter (closed December 9, 2019): 'FDA has no questions'. [P3]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- No IARC or NTP carcinogenicity evaluation of Bifidobacterium animalis subsp. lactis BB-12 was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-30). [P6]
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- Antibiotics (timing): Health Canada's probiotics monograph directs taking the bacteria in its Table 1, which includes Bifidobacterium animalis subsp. lactis, at least 2–3 hours before or after antibiotics. [P5]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P8]
- Strain identity by phenotype and genotype (genome-based comparison to type strains and whole-genome strain characterization) — Required by Health Canada's probiotics monograph for each live microorganism. [P5]
- Viable count (CFU) at end of shelf life — Health Canada requires at least 80% of the label-declared quantity at the end of shelf life. [P5]
Supply and conservation
- No published information found in the sources checked.
Absorption in people
- In the infant trial, BB-12 was recovered (qPCR, detection limit log 5) in the feces of 62% of infants receiving BB-12 tablets at 8 months of age. [P4]
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- Health Canada probiotics monograph (April 24, 2026), Table 1 bacteria including Bifidobacterium animalis subsp. lactis: 1.0 x 10^7 total CFU or more per day (total from all live microorganisms in the product) for its general uses. [P5]
Pregnancy and breastfeeding
- No published information found in the sources checked.
Sources for this profile
- Masco L, et al. Polyphasic taxonomic analysis of Bifidobacterium animalis and Bifidobacterium lactis reveals relatedness at the subspecies level: reclassification of Bifidobacterium animalis as Bifidobacterium animalis subsp. animalis subsp. nov. and Bifidobacterium lactis as Bifidobacterium animalis subsp. lactis subsp. nov. Int J Syst Evol Microbiol 2004;54(Pt 4):1137-1143 (PMID 15280282), 2004-07. pubmed.ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- FDA. GRAS Notice Inventory: GRN No. 856, Bifidobacterium animalis subsp. lactis strain BB-12 (date of closure Dec 9, 2019), 2019-12-09. hfpappexternal.fda.gov
- Taipale T, et al. Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in infancy. Br J Nutr 2011;105(3):409-16 (PMID 20863419), 2011-02. pubmed.ncbi.nlm.nih.gov
- Health Canada, NNHPD. Natural health product monograph: Probiotics (date April 24, 2026), 2026-04-24. webprod.hc-sc.gc.ca
- IARC Monographs. List of Classifications: agents classified by the IARC Monographs, Volumes 1–142 (last updated 2026-07-23), 2026-07-23. monographs.iarc.who.int
- National Toxicology Program. Technical Reports (TR series index, TR-001 to TR-606; checked 2026-10-30), 2026-10-30. ntp.niehs.nih.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
Sources
- Masco L, et al. Polyphasic taxonomic analysis of Bifidobacterium animalis and Bifidobacterium lactis reveals relatedness at the subspecies level: reclassification of Bifidobacterium animalis as Bifidobacterium animalis subsp. animalis subsp. nov. and Bifidobacterium lactis as Bifidobacterium animalis subsp. lactis subsp. nov. Int J Syst Evol Microbiol 2004;54(Pt 4):1137-1143 (PMID 15280282), 2004-07. pubmed.ncbi.nlm.nih.gov
- Jungersen M, et al. The science behind the probiotic strain Bifidobacterium animalis subsp. lactis BB-12. Microorganisms 2014;2(2):92-110 (PMID 27682233), 2014-03-28. pubmed.ncbi.nlm.nih.gov
- Kumar A, et al. Safety of one of the most commonly used probiotic strains: systematic review and meta-analysis of reported adverse events. Probiotics Antimicrob Proteins 2026;18(3):4037-4048 (Epub 2025 Sep 2) (PMID 40892162), 2026-04. pubmed.ncbi.nlm.nih.gov
- Kumar A, et al. Safety of one of the most commonly used probiotic strains: systematic review and meta-analysis of reported adverse events. Probiotics Antimicrob Proteins (Epub 2025 Sep 2), Supplementary Material, Table S2: published AE rates in all 19 meta-analysis studies, 2025-09-02. static-content.springer.com
- Eskesen D, et al. Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial. Br J Nutr 2015;114(10):1638-46 (PMID 26382580), 2015-11-28. pubmed.ncbi.nlm.nih.gov
- Chen K, et al. Efficacy of Bifidobacterium animalis subsp. lactis, BB-12 on infant colic - a randomised, double-blinded, placebo-controlled study. Benef Microbes 2021;12(6):531-540 (PMID 34550055), 2021-11-16. pubmed.ncbi.nlm.nih.gov
- Nocerino R, et al. The therapeutic efficacy of Bifidobacterium animalis subsp. lactis BB-12 in infant colic: a randomised, double blind, placebo-controlled trial. Aliment Pharmacol Ther 2020;51(1):110-120 (PMID 31797399), 2020-01. pubmed.ncbi.nlm.nih.gov
- Taipale T, et al. Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in infancy. Br J Nutr 2011;105(3):409-16 (PMID 20863419), 2011-02. pubmed.ncbi.nlm.nih.gov
- Acuña Ponce de León EG, et al. Effects of Bifidobacterium lactis BB12 probiotic consumption on Streptococcus mutans levels: a systematic review of randomized clinical trials. Rev Cient Odontol (Lima) 2026;14(2):e287 (PMID 42256686), 2026-04-04. pubmed.ncbi.nlm.nih.gov
- Szajewska H, Chmielewska A. Growth of infants fed formula supplemented with Bifidobacterium lactis Bb12 or Lactobacillus GG: a systematic review of randomized controlled trials. BMC Pediatr 2013;13:185 (PMID 24215626), 2013-11-12. pubmed.ncbi.nlm.nih.gov
- Tan TP, et al. Safety of Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12-supplemented yogurt in healthy children. J Pediatr Gastroenterol Nutr 2017;64(2):302-309 (PMID 28114246), 2017-02. pubmed.ncbi.nlm.nih.gov
- NIH Office of Dietary Supplements. Probiotics: Fact Sheet for Health Professionals (Updated March 25, 2025), 2025-03-25. ods.od.nih.gov
- Health Canada, NNHPD. Natural health product monograph: Probiotics (date April 24, 2026), 2026-04-24. webprod.hc-sc.gc.ca
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- FDA. GRAS Notice Inventory: GRN No. 856, Bifidobacterium animalis subsp. lactis strain BB-12 (date of closure Dec 9, 2019), 2019-12-09. hfpappexternal.fda.gov
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in probiotic: Akkermansia muciniphila (pasteurized) · Bacillus coagulans (Heyndrickxia coagulans) · Escherichia coli Nissle 1917 (EcN) · Lacticaseibacillus paracasei strain Shirota (LcS) · Lacticaseibacillus rhamnosus GG (LGG) · Lactiplantibacillus plantarum 299v · Limosilactobacillus reuteri DSM 17938 · Probiotics · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.